香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 香港，二零二五年八月六日 於本公告日期，本公司董事包括 (i) 執行董事：林剛先生及陳燕玲女士； (ii) 非執行董事： 陳洪兵先生； (iii) 獨立非執行董事：梁創順先生、羅瑩女士及馮征先生。 *僅供識別 1 董事會會議通告 China Medical System Holdings Limited（「本公司」）董事會（「董事會」）茲通告，本公 司謹定於二零二五年八月十八日（星期一）召開本公司董事會會議，其中包括考慮及擬 批准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業績，及考慮派發 中期股息（如有）。 承董事會命 China Medical System Holdings Limited 主席 林剛 ...

Group 1 - The core viewpoint is that the liquidity and fundamentals of the Chinese healthcare industry continue to improve, maintaining a positive outlook for the healthcare sector [1] - The report indicates that the weak U.S. employment data may lead to heightened expectations for monetary easing in the second half of the year, suggesting an improved outlook for the industry [1] - The report highlights that the industry fundamentals are recovering, with a month-on-month increase in hospital prescription volumes in July, and significant profit growth expected in the third quarter due to the release of more innovative drugs [1] Group 2 - The company prefers leading large pharmaceutical firms and suggests avoiding companies overly reliant on biosimilars in the short term [2] - Selected stocks include: CSPC Pharmaceutical Group (01093), Sinopharm Group (01099), Hansoh Pharmaceutical (03692), and others [2] - The report emphasizes that the uncertainty in U.S. Treasury yields may prompt a reallocation of funds, further improving the liquidity of innovative drug assets [1]

里昂指出，行业基本面持续复苏，7月院内处方量环比提升，随着更多创新药放量，第三季行业盈利有 望实现显著增长，加上美债不确定性可能促使资金重新配置，进一步改善创新药资产流动性，相信行业 拐点已过，未来将迎来盈喜等正面催化剂。 该行偏好领先大型药厂，短期而言避开过度依赖生物仿制药的公司。该行选股包括石药集团(01093)、 新诺威(300765.SZ)、翰森制药(03692)、爱尔眼科(300015.SZ)、恒瑞医药(01276,600276.SH)、康方生物 (09926)、中生制药(01177)、国药控股(01099)、康哲药业(00867)、大参林(603233.SH)、华东医药 (000963.SZ)、泰格医药(03347)及药明康德(02359)。 智通财经APP获悉，里昂发布研报称，中国医疗健康行业流动性及基本面持续改善，维持对医疗健康板 块正面看法，指出美国就业数据疲软或市场对下半年货币宽松预期急升温，预示着行业下半年改善前 景，相信特朗普再提最惠国药品定价政策及安徽启动生物类似药集中采购，对行业影响则相对有限。 ...

截至月份: 2025年7月31日 狀態: 新提交 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: China Medical System Holdings Limited 康哲藥業控股有限公司*（*僅供識別） 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00867 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | USD | USD | 0.005 | | 100,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 20,000,000,000 | USD | ...

| 股份代號: | 00867 | | --- | --- | | 上市法國名稱: | 康哲藥業控股有限公司 | | 日期 (日 / 月 / 年): | 01/07/2025 - 01/08/2025 | 格隆汇8月1日丨根据联交所最新权益披露资料显示，2025年7月29日，康哲药业(00867.HK)遭Lazard Asset Management LLC在场内以每股均价13.7518港元减 持774.2万股，涉资约1.06亿港元。 减持后，Lazard Asset Management LLC最新持股数目为121,070,000股，持股比例由5.28%下降至4.96%。 | 麦格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | | | 時代言 | | | | (語参照上述 * 註 有投票權股 (日 / 月 / 年) | | | | | | | | | 防信分同 | | | | | | | | 961 | | ...

Company News - China Railway Construction (01186.HK) reported a new contract amount of approximately 1,056.17 billion yuan for the first half of the year, a year-on-year decrease of 4.04% [2] - China Metallurgical Group (01618.HK) announced a new contract amount of 548.2 billion yuan for the first half of the year, down 19.1% year-on-year [2] - Sichuan Chengyu Expressway (00107.HK) won the bid for the G5 Jingkun Expressway Chengdu to Ya'an section expansion project, with a total investment of approximately 28.548 billion yuan [2] - Road King Infrastructure (01098.HK) reported total property sales of 5.232 billion yuan for the first half of the year, a decrease of 28.37% year-on-year [2] - Amax Holdings (00880.HK) plans to acquire a property in Hengqin for 724.2 million yuan to diversify its business portfolio [2] - Chaoyue Eye Hospital (02219.HK) signed a construction contract for the first phase of its comprehensive medical facility project, with a contract value of 223 million yuan [2] - Bay Area Development (00737.HK) reported total toll revenue of 243 million yuan for June, a year-on-year decrease of 4% [2] - Decent Pharmaceuticals-B (06996.HK) received approval for its drug, Hivio®, for the second-line treatment of multiple myeloma in China [2] - Tianchen Holdings (01201.HK) plans to invest 30 million yuan to establish a joint venture in Shenzhen for new energy heavy truck charging stations [2] Performance Summary - WuXi AppTec (02359.HK) reported mid-year revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit of 8.561 billion yuan, up 101.92% year-on-year [3] Earnings Announcements - China Nonferrous Mining (01258.HK) issued a profit warning, expecting mid-term net profit of approximately 258 million USD, a year-on-year increase of about 18% [4] - Hualing Pharmaceutical-B (02552.HK) issued a profit warning, expecting mid-term net profit of approximately 1.184 billion yuan, turning from loss to profit [4] - Little Yellow Duck (02250.HK) issued a profit warning, expecting mid-term revenue to increase by over 30% year-on-year [4] - Qingci Games (06633.HK) issued a profit warning, expecting mid-term net profit to increase by approximately 78%-130% year-on-year [4] - Goodbaby International (01086.HK) issued a profit warning, expecting mid-term net profit to decrease by approximately 40%-50% year-on-year [4] - Qianhai Health (00911.HK) issued a profit warning, expecting mid-term net profit to decrease by approximately 60%-70% year-on-year [4] - Tianan Health (00383.HK) issued a profit warning, expecting mid-term net profit to decrease to approximately 7 million to 17 million HKD [4] - Pacific Network (00543.HK) issued a profit warning, expecting mid-term net loss of approximately 5 million to 15 million yuan [4] Buyback and Increase Dynamics - HSBC Holdings (00005.HK) repurchased 348,700 shares for approximately 35.487 million HKD at a price of 101.4-102 HKD [3] - China Eastern Airlines (00670.HK) repurchased 2.5 million shares for approximately 7.4983 million HKD at a price of 2.97-3.03 HKD [3] - Founder Holdings (00418.HK) canceled a total of 17.9962 million shares that had been repurchased [3]

Core Viewpoint - 康哲药业's new drug ZUNVEYL has received acceptance for its New Drug Application (NDA) from the National Medical Products Administration (NMPA) in China, aimed at treating mild to moderate Alzheimer's disease symptoms [1] Group 1: Product Details - ZUNVEYL is a new generation acetylcholinesterase inhibitor (AChEI) that improves cognitive and memory functions in Alzheimer's patients by increasing central acetylcholine levels [2] - The drug is a prodrug of galantamine, designed to reduce gastrointestinal side effects and improve patient tolerance, with recorded gastrointestinal adverse events below 2% [2] - ZUNVEYL is the second oral therapy for Alzheimer's approved by the FDA in the last decade, potentially enhancing medication adherence among patients [2] Group 2: Market Context - Alzheimer's disease is a chronic neurodegenerative condition, with Alzheimer's-type dementia accounting for 50% to 70% of all dementia cases, affecting approximately 9.83 million patients in China [3] - The increasing aging population is expected to raise the number of Alzheimer's patients, intensifying the disease burden [3] - Current Alzheimer's medications primarily focus on improving cognitive symptoms, with a significant demand for safer treatment options due to high side effect rates of existing drugs [3] Group 3: Strategic Partnerships - 康哲药业 has signed a licensing and collaboration agreement with Alpha Cognition Inc. for ZUNVEYL, granting exclusive rights for development and commercialization in Asia (excluding Japan and the Middle East), Australia, and New Zealand [4] - The agreement is set for an initial term of twenty years, with automatic five-year extensions unless terminated by either party [4] - ZUNVEYL is expected to diversify 康哲药业's innovative drug portfolio and enhance its competitive strength in the market, potentially benefiting the company's performance upon approval [4]

自願性及業務進展公告 就治療輕度至中度阿爾茨海默型癡呆症狀的 改良型新藥ZUNVEYL中國上市許可申請已獲受理 China Medical System Holdings Limited（「本公司」，連同其附屬公司統稱為「本集團」） 欣然宣佈，改良型新藥ZUNVEYL（擬定通用名：葡萄糖酸苯加蘭他敏腸溶片） （「ZUNVEYL」或「產品」）新藥上市許可申請（NDA）已於二零二五年七月二十八 日獲得中國國家藥品監督管理局（NMPA）受理。產品擬用於治療成人輕度至中度阿爾 茨海默型癡呆症狀。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃由本公司自願刊發，旨在向潛在投資者及本公司股東通知本集團最新業務進 展，建議股東和投資者在進行本公司股票及其他證券的交易時謹慎操作。 ZUNVEYL於二零二四年七月獲得美國食品和藥物管理局（FDA）批准上市用於治療成 人輕度至中度阿爾茨海默型癡呆症狀，屬於新一代乙酰膽鹼酯酶抑制劑（AChEI），通 過抑制乙酰膽鹼酯酶 ...

Core Viewpoint - Hunan Maijie Biotechnology Co., Ltd. (Maijie Bio) has submitted its IPO application to the Hong Kong Stock Exchange, with a valuation that has increased nearly 45 times since its establishment in 2016, despite ongoing financial losses and no product revenue as of the end of 2024 [1][4][12] Valuation and Financing - Since its inception, Maijie Bio has raised over 700 million RMB through multiple financing rounds, with a post-money valuation rising from approximately 58 million RMB in 2017 to 2.64 billion RMB in 2025 [2][4] - The company’s valuation has significantly increased, with the latest Pre-IPO round raising 260 million RMB, doubling its valuation to 2.64 billion RMB [4][6] - The company faces stringent buyback clauses in early investment agreements, which could pressure it to go public by the end of 2025 [4][6] Financial Performance - In 2023, Maijie Bio reported revenue of only 8.72 million RMB, with R&D expenses reaching 166 million RMB, resulting in a net loss of 253 million RMB [4][5] - The company anticipates a continued increase in losses, with no revenue recorded in Q1 2025 and R&D spending of 24.3 million RMB [5][6] - By the end of Q1 2025, the company had cash reserves of only 70.78 million RMB, highlighting a significant funding gap against its projected R&D budget [6] Product Development and Market Strategy - Maijie Bio's core product, MG-K10, is a long-acting antibody targeting allergic diseases, which has entered Phase III clinical trials [1][6][10] - The company has partnered with Kangzhe Pharmaceutical for exclusive commercialization rights in certain regions, which includes shared clinical costs, providing immediate cash flow and reducing financial pressure [8][9] - The collaboration is structured to minimize upfront payments while maximizing potential future revenue through milestone payments based on sales performance [8][10] Market Potential - The long-acting IL-4Rα antibody market in China is projected to reach approximately 23.8 billion RMB by 2032, with Maijie Bio aiming for a 25% market share, potentially generating annual sales of around 6 billion RMB [10][11] - The partnership with Kangzhe is expected to enhance Maijie Bio's market access and operational capabilities, leveraging Kangzhe's established distribution network [9][11] Future Outlook - The upcoming years are critical for Maijie Bio as it navigates high cash burn rates and clinical uncertainties while facing competition and regulatory pressures [12] - The success of the IPO and subsequent product commercialization will depend on clinical trial outcomes and market acceptance [12]

Group 1 - The core viewpoint of the news is the performance and holdings of the Ping An Low Carbon Economy Mixed A fund, which has shown positive growth in recent months and has a significant portion of its assets allocated to top-performing stocks [1][3]. - As of July 23, 2025, the latest net value of the Ping An Low Carbon Economy Mixed A fund is 1.0878 yuan, reflecting a growth of 1.04%. The fund has achieved a return of 5.83% over the past month, 18.07% over the past six months, and 17.20% year-to-date [1]. - The fund's top ten stock holdings account for a total of 68.78%, with notable investments in companies such as Gigabyte (9.02%), Gree Electric Appliances (8.50%), and Xpeng Motors (8.33%) [1]. Group 2 - The Ping An Low Carbon Economy Mixed A fund was established on August 10, 2020, and as of June 30, 2025, it has a total scale of 1.427 billion yuan, managed by fund manager He Jie [1]. - He Jie has a background in finance, holding a master's degree from the University of Augsburg in Germany, and has held various positions in investment management and research prior to joining Ping An Fund Management Company in August 2021 [2].